Beyond Triple Agonists: Quadruple Targets?

Next-Gen Obesity Peptides

28.7% weight loss

The triple agonist retatrutide achieved 28.7% mean body weight reduction in Phase 3, the highest ever reported in an obesity trial. Now researchers are asking: can a fourth receptor push that number higher?

Eli Lilly, TRIUMPH-4, 2025

Eli Lilly, TRIUMPH-4, 2025

View as image

The first generation of GLP-1 receptor agonists delivered 15-17% weight loss. Tirzepatide, a dual GLP-1/GIP agonist, pushed that to 22.5%. Retatrutide, the first triple GLP-1/GIP/glucagon receptor agonist to reach Phase 3, produced 28.7% mean weight loss at 68 weeks in the TRIUMPH-4 trial.^[1] Each additional receptor target has added roughly 5-7 percentage points of weight loss. The obvious question: what happens when you add a fourth?

This is not hypothetical. At least two quadruple receptor agonist candidates have entered or are entering clinical trials, and multiple research groups are exploring novel receptor combinations that go beyond the current GLP-1/GIP/glucagon framework. For context on where these molecules fit in the broader pipeline, see every obesity peptide in the pipeline. For the oral approach to next-gen obesity drugs, see orforglipron.

The Receptor Escalation: Single to Triple

The path from single to triple receptor agonism has been remarkably consistent in its results. Each step added a new metabolic pathway and improved weight loss outcomes.

Single agonism (GLP-1 alone). Semaglutide and liraglutide activate only the GLP-1 receptor, reducing appetite through brainstem satiety signaling, slowing gastric emptying, and improving insulin secretion. The STEP trials showed semaglutide 2.4 mg produced approximately 15-17% weight loss. For more on this class, see semaglutide for weight loss.

Dual agonism (GLP-1 + GIP). Tirzepatide activates both GLP-1 and GIP receptors. The addition of GIP agonism improved weight loss to 22.5% in the SURMOUNT trials. GIP receptor activation enhances insulin sensitivity and may contribute to fat metabolism in adipose tissue.

Triple agonism (GLP-1 + GIP + glucagon). Retatrutide adds glucagon receptor activation to the dual agonist framework. Glucagon increases energy expenditure through thermogenesis and hepatic fat oxidation. Jastreboff et al. (2023) published the Phase 2 data in the New England Journal of Medicine, showing up to 24.2% weight loss at 48 weeks across dose groups.^[2] The Phase 3 TRIUMPH-4 results, announced in August 2025, extended this to 28.7% at 68 weeks.

Knerr et al. (2022) provided the preclinical foundation for this approach, demonstrating that next-generation GLP-1/GIP/glucagon triple agonists normalized body weight in obese mice.^[3] Ganamurali et al. (2026) described the triple-agonist revolution as a "paradigm shift in multi-hormonal pharmacotherapy."^[1]

The Fourth Receptor: Three Leading Candidates

Amylin: The Satiety Amplifier

The most clinically advanced "fourth pathway" uses amylin receptor agonism. Amylin is a pancreatic peptide co-secreted with insulin that promotes satiety through brainstem signaling. Carvas et al. (2025) demonstrated that cagrilintide, a long-acting amylin analog, lowers bodyweight specifically through brain amylin receptors 1 and 3.^[4]

CagriSema, Novo Nordisk's co-formulation of cagrilintide and semaglutide, effectively adds amylin agonism to GLP-1 agonism. Garvey et al. (2025) reported the REDEFINE 1 results: 22.7% mean weight loss at 68 weeks in adults with overweight or obesity, with Novo Nordisk filing a New Drug Application in December 2025.^[5]

CagriSema's 22.7% weight loss is notable because it approaches triple agonist territory using only two receptor targets. The implication: combining amylin agonism with a triple agonist like retatrutide could theoretically produce weight loss beyond 30%. This four-pathway approach (GLP-1 + GIP + glucagon + amylin) has not yet been tested in humans, but the pharmacological rationale is strong and each component has independent clinical evidence supporting its contribution to weight reduction.

IGF-1: The Muscle-Sparing Target

One of the main concerns with aggressive weight loss is lean mass loss. Approximately 25-40% of weight lost with GLP-1 agonists can be muscle mass, which creates particular risks for older adults. See GLP-1 weight loss and sarcopenia for the evidence on this risk.

The quadruple agonist NA-931, presented at the American Diabetes Association 2025 meeting, targets IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. The preclinical data showed body weight reduction without the muscle loss typically associated with GLP-1 class drugs. By incorporating IGF-1 receptor agonism, an anabolic pathway that promotes protein synthesis and muscle maintenance, the molecule attempts to solve the body composition problem inherent in current obesity pharmacotherapy.

A separate quadruple agonist candidate, bioglutide, is an oral IGF-1/GLP-1/GIP/glucagon agonist that has entered Phase 2 trials (NCT06564753), including a combination study with tirzepatide (NCT06643728). If successful, it would be the first oral quadruple agonist, combining the receptor breadth of retatrutide with the muscle-sparing properties of IGF-1 agonism in a non-injectable format.

NPY2R: The Satiety Circuit Alternative

Neuropeptide Y receptor Y2 (NPY2R) represents a different approach to the "fourth target" question. Rather than adding another incretin or metabolic receptor, NPY2R agonism targets the gut-brain satiety circuit through a pathway distinct from GLP-1.

Yuan et al. (2023) discovered a potent and long-acting GLP-1/glucagon/Y2 receptor triple agonist based on Xenopus GLP-1, demonstrating that Y2R agonism provides additive weight loss when combined with incretin receptor activation.^[6]

Augustin et al. (2025) provided the strongest evidence for this approach with BI 1820237, a novel NPY2R agonist that showed synergistic anti-obesity efficacy when combined with a dual GLP-1/glucagon agonist (survodutide).^[7] The word "synergistic" is significant: it means the combination produced more weight loss than the sum of either agent alone, suggesting the two pathways amplify each other rather than simply adding their effects. This is the pharmacological signature of a genuinely novel combination.

The Dual Agonist Landscape: Platforms for the Fourth Target

Understanding the current dual agonists is essential because they serve as the base molecules onto which fourth targets are being added.

Survodutide (GLP-1/glucagon dual agonist, Boehringer Ingelheim/Zealand Pharma) produced approximately 19% weight loss in the Phase 2 ACHIEVE trial.^[8] It has a unique position in the pipeline because Phase 2 data also showed MASH (metabolic dysfunction-associated steatohepatitis) resolution, making it a potential two-indication drug. The Phase 3 SYNCHRONIZE program is underway. Adding NPY2R agonism to survodutide's GLP-1/glucagon base (as Augustin et al. explored) represents one path to a triple or quadruple molecule.

Pemvidutide (GLP-1/glucagon dual agonist, Altimmune) targets both obesity and liver disease. Browne et al. (2025) reported 24-week safety and efficacy data showing benefits in MASH.^[9] For more on this molecule, see pemvidutide.

Chan et al. (2026) published a systematic review and meta-analysis of all incretin-based dual and triple agonists in overweight or obese individuals, providing the most comprehensive comparison of efficacy across the multi-agonist landscape.^[10]

Why More Receptors Is Not Automatically Better

Alavi et al. (2026) reviewed the rise of multi-target incretin-based therapeutics and identified both the promise and the risks.^[11] Several factors complicate the "add more receptors" strategy.

Diminishing returns. Each additional receptor adds weight loss, but the marginal gain may decrease as the absolute loss approaches physiological limits. The human body has compensatory mechanisms that resist weight loss, including metabolic rate reduction, hormonal adaptations (leptin, ghrelin), and behavioral changes. At some point, receptor-level pharmacology will encounter these systemic brakes.

Safety complexity. More receptor targets means more off-target effects to manage. Glucagon receptor activation increases energy expenditure, but it also raises blood glucose and has the potential to cause hepatotoxicity at high doses. IGF-1 agonism promotes muscle preservation, but chronic IGF-1 elevation is associated with cancer risk. Each new pathway adds benefits but also adds a new set of safety signals to monitor.

Manufacturing and formulation. Designing a single molecule that activates four receptors with the optimal ratio of potency at each is a substantial medicinal chemistry challenge. The balance matters: retatrutide's success partly reflects careful tuning of its relative activity at GLP-1, GIP, and glucagon receptors. Adding a fourth target multiplies the optimization space.

Gastrointestinal tolerability. The dominant side effects of all GLP-1 class drugs are nausea, vomiting, and diarrhea. As efficacy increases, so does the incidence and severity of these effects. The dose-response data from retatrutide Phase 2 showed that the highest doses produced the most weight loss but also the most GI side effects.^[2] A quadruple agonist would likely need novel approaches to tolerability.

The Combination vs. Single-Molecule Debate

CagriSema's approach, co-formulating two separate peptides rather than engineering one molecule with multiple receptor activities, represents a fundamentally different strategy than the single-molecule multi-agonists.

The combination approach offers flexibility: each component can be independently dose-optimized. CagriSema's cagrilintide dose can be adjusted relative to its semaglutide dose without re-engineering the molecule. The downside: two peptides means two manufacturing processes, potentially higher cost, and a more complex regulatory path.

Single-molecule agonists like retatrutide and the emerging quadruple agonists are more elegant pharmacologically but harder to optimize. The ratio of activity at each receptor is fixed by the molecular structure. If clinical data reveals that a different balance of GLP-1 to glucagon activity would be better, the molecule must be redesigned.

This debate is likely to be resolved by clinical data rather than theory. The cost-effectiveness of GLP-1s will also influence which approach prevails commercially. For the impact on cardiovascular outcomes, see GLP-1 drugs and heart disease.

What the Evidence Supports

The triple agonist approach has Phase 3 validation. Retatrutide's 28.7% weight loss is the benchmark, and survodutide and CagriSema are generating their own large-scale data. The scientific case for adding a fourth receptor target rests on solid preclinical evidence and mechanistic reasoning but lacks human efficacy data.

NA-931 and bioglutide are the first quadruple agonists to reach clinical development, but their data is early-stage. The NPY2R combination data from Augustin et al. (2025) is compelling but also preclinical. The amylin pathway has the strongest clinical support, through CagriSema's Phase 3 data, but the combination of all four pathways (GLP-1 + GIP + glucagon + amylin) has not been tested.

The field is moving fast. By the end of 2026, Phase 2 data from at least one quadruple agonist candidate should be available, and the SYNCHRONIZE Phase 3 results for survodutide will further define the dual GLP-1/glucagon efficacy ceiling. Whether the fourth receptor delivers the incremental benefit needed to justify the added complexity remains the central unanswered question.

The Bottom Line

The progression from single to dual to triple receptor agonists has consistently increased weight loss efficacy in obesity treatment. Quadruple agonist candidates targeting IGF-1, amylin, or NPY2R pathways alongside existing GLP-1/GIP/glucagon combinations have entered early clinical development. The preclinical rationale is strong, particularly for muscle-sparing IGF-1 combinations and synergistic NPY2R approaches, but human efficacy data is not yet available. The coming 12-18 months will determine whether adding a fourth receptor target meaningfully exceeds what triple agonists already achieve.

Frequently Asked Questions

What is a quadruple agonist for weight loss?

A quadruple receptor agonist is a molecule designed to activate four different metabolic receptors simultaneously to produce greater weight loss than current drugs. The most advanced candidates target GLP-1, GIP, glucagon, and either IGF-1 (for muscle preservation) or amylin (for enhanced satiety) receptors. NA-931 is one such candidate that showed weight loss without muscle loss in preclinical data.

How much weight loss can triple agonists achieve?

Retatrutide, the first triple GLP-1/GIP/glucagon receptor agonist in Phase 3 trials, produced 28.7% mean body weight reduction at 68 weeks in the TRIUMPH-4 trial.^[2] The Phase 2 data had shown up to 24.2% at 48 weeks. This is the highest weight loss ever reported in a large-scale obesity drug trial.

What is CagriSema and how does it work?

CagriSema is Novo Nordisk's combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog) in a single injection. It produced 22.7% weight loss at 68 weeks in the REDEFINE 1 trial.^[5] An NDA was filed in December 2025. It targets two satiety pathways through different mechanisms rather than combining them in one molecule.

What is retatrutide and when will it be available?

Retatrutide is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, currently in Phase 3 trials across the TRIUMPH program. Phase 3 data showed 28.7% weight loss at 68 weeks. If approved, it would likely be available in 2027 or 2028. Additional results including maintenance dosing data are expected throughout 2026.

Do multi-agonist weight loss drugs cause muscle loss?

Muscle loss is a significant concern with all current GLP-1 class weight loss drugs: approximately 25-40% of weight lost can be lean mass. The quadruple agonist NA-931, which adds IGF-1 receptor agonism to the GLP-1/GIP/glucagon combination, was specifically designed to preserve muscle during weight loss. Retatrutide Phase 2 body composition data showed that glucagon receptor activation shifted the weight loss ratio toward more fat loss and less lean mass loss.^[2]

What are the risks of activating more receptors?

Each additional receptor target adds both benefits and new safety signals. Glucagon receptor activation increases energy expenditure but can raise blood glucose. IGF-1 agonism preserves muscle but chronic elevation is linked to cancer risk. More receptor targets also increase GI side effects (nausea, vomiting) and create greater manufacturing complexity. The dose-response data from retatrutide showed that higher efficacy came with higher rates of gastrointestinal adverse events.^[11]